HUE054783T2 - Pridopidin Huntington-kór kezelésében - Google Patents

Pridopidin Huntington-kór kezelésében

Info

Publication number
HUE054783T2
HUE054783T2 HUE14813621A HUE14813621A HUE054783T2 HU E054783 T2 HUE054783 T2 HU E054783T2 HU E14813621 A HUE14813621 A HU E14813621A HU E14813621 A HUE14813621 A HU E14813621A HU E054783 T2 HUE054783 T2 HU E054783T2
Authority
HU
Hungary
Prior art keywords
pridopidine
disease
treating huntington
huntington
treating
Prior art date
Application number
HUE14813621A
Other languages
English (en)
Inventor
Merav Bassan
Eli Eyal
Esther Hagai
Teige Wickenberg Anna Sveinsdotter
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE054783(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of HUE054783T2 publication Critical patent/HUE054783T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
HUE14813621A 2013-06-21 2014-06-19 Pridopidin Huntington-kór kezelésében HUE054783T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
HUE054783T2 true HUE054783T2 (hu) 2021-09-28

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14813621A HUE054783T2 (hu) 2013-06-21 2014-06-19 Pridopidin Huntington-kór kezelésében

Country Status (24)

Country Link
US (1) US10322119B2 (hu)
EP (1) EP3010506B1 (hu)
JP (1) JP2016523862A (hu)
KR (1) KR102316933B1 (hu)
CN (1) CN105592848A (hu)
AU (1) AU2014281414A1 (hu)
BR (1) BR112015029918A2 (hu)
CA (1) CA2913781C (hu)
CL (1) CL2015003690A1 (hu)
DK (1) DK3010506T3 (hu)
EA (1) EA201690069A1 (hu)
ES (1) ES2879631T3 (hu)
HK (1) HK1221646A1 (hu)
HU (1) HUE054783T2 (hu)
IL (1) IL242804B (hu)
MX (1) MX2015017307A (hu)
PE (2) PE20160195A1 (hu)
PH (1) PH12015502691A1 (hu)
PL (1) PL3010506T3 (hu)
SG (1) SG11201509729YA (hu)
TW (1) TW201529069A (hu)
UA (1) UA122999C2 (hu)
UY (1) UY35624A (hu)
WO (1) WO2014205229A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US20150202302A1 (en) * 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
HUE060353T2 (hu) * 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CA2993183A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
EP3504187A4 (en) * 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE
MX2019002190A (es) * 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
WO2018053287A1 (en) * 2016-09-15 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of anxiety and depression
CA3036984C (en) 2016-09-16 2023-07-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating rett syndrome
CN110505902B (zh) 2017-01-20 2022-11-11 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗脆性x综合征的应用
EP3668509B1 (en) 2017-08-14 2022-11-16 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
CA3073568A1 (en) 2017-08-30 2019-03-07 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
CN111343982A (zh) 2017-09-08 2020-06-26 普瑞尼亚神经治疗有限公司 用于治疗药物诱发的异动症的普利多匹定
WO2020250234A1 (en) * 2019-06-12 2020-12-17 Prilenia Neurotherapeutics Ltd. Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
WO2021055443A1 (en) * 2019-09-17 2021-03-25 Hoffmann-La Roche Inc. Improvements in personalized healthcare for patients with movement disorders
US20230390232A1 (en) * 2020-10-28 2023-12-07 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
EP1815857A1 (en) * 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
PT2146961E (pt) 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EA023462B1 (ru) 2011-09-07 2016-06-30 Тева Фармасьютикалз Интернэшнл Гмбх Полиморфная форма гидрохлорида придопидина
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
CA2869145A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
EP2900226A4 (en) 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
US20140088140A1 (en) 2012-09-27 2014-03-27 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
US20150202302A1 (en) 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
HUE060353T2 (hu) 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
EP3504187A4 (en) 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE
WO2018053287A1 (en) 2016-09-15 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of anxiety and depression
CA3036984C (en) 2016-09-16 2023-07-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating rett syndrome
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia

Also Published As

Publication number Publication date
PL3010506T3 (pl) 2021-11-02
PE20160195A1 (es) 2016-05-14
CA2913781A1 (en) 2014-12-24
SG11201509729YA (en) 2015-12-30
US10322119B2 (en) 2019-06-18
HK1221646A1 (zh) 2017-06-09
PE20170302A1 (es) 2017-03-31
ES2879631T3 (es) 2021-11-22
WO2014205229A8 (en) 2015-04-09
UA122999C2 (uk) 2021-02-03
KR20160055122A (ko) 2016-05-17
CL2015003690A1 (es) 2016-10-28
BR112015029918A2 (pt) 2017-07-25
PH12015502691A1 (en) 2016-03-14
EP3010506A4 (en) 2017-02-08
WO2014205229A1 (en) 2014-12-24
CA2913781C (en) 2022-05-10
JP2016523862A (ja) 2016-08-12
DK3010506T3 (da) 2021-07-12
TW201529069A (zh) 2015-08-01
IL242804B (en) 2022-02-01
MX2015017307A (es) 2016-08-03
AU2014281414A1 (en) 2016-01-21
EP3010506A1 (en) 2016-04-27
UY35624A (es) 2015-01-30
EA201690069A1 (ru) 2016-06-30
KR102316933B1 (ko) 2021-10-26
EP3010506B1 (en) 2021-05-12
CN105592848A (zh) 2016-05-18
US20140378508A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
PL3010506T3 (pl) Pridopidyna w leczeniu choroby huntingtona
EP3068905A4 (en) Methods and compositions for treating huntington's disease
ZA201406209B (en) Methods and compositions for treating huntington's disease
EP2978446A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP3086846A4 (en) Diagnosing and treating alzheimer's disease
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
EP2968452A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NETWORK DISEASES
GB201310203D0 (en) Materials and methods relating to Alzheimer's disease
PT2980096T (pt) Métodos de preparação de 2,3,5 tri-hidroxi-androst-6-ona e utilização do mesmo
HK1223827A1 (zh) 用於治療眼疾病的 調節劑
ZA201407032B (en) Preventing or treating periodontal disease
AU353890S (en) Men's clothing
GB201214450D0 (en) Huntington's disease
GB201309694D0 (en) Artist's implement
GB201310607D0 (en) B'jamas
GB201310101D0 (en) Treatment of freidreich's ataxia
GB201322568D0 (en) Taggstar 1
BR302013005287S1 (pt) Configuração introduzida em calçado feminino
AU350798S (en) Alu' sling sunlounger
GB201320379D0 (en) Concept 82
GB201309270D0 (en) Line-out Rugby aid 'Get Up's'
GB201310407D0 (en) Plantladders 3
GB201301407D0 (en) 17 Deemed-Ties Blackjack
GB201310285D0 (en) Twist-Away 270
GB201311522D0 (en) Concept 40